Y. Agata, A. Kawasaki, H. Nishimura, Y. Ishida, T. Tsubata et al., Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes, International Immunology, vol.8, issue.5, pp.765-772, 1996.
DOI : 10.1093/intimm/8.5.765

E. A. Akbay, S. Koyama, J. Carretero, A. Altabef, T. J. Christensen et al., Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors, Cancer Discovery, vol.3, issue.12, pp.1355-63, 2013.
DOI : 10.1158/2159-8290.CD-13-0310

A. Antonelli, C. Ferri, P. Fallahi, D. Giuggioli, C. Nesti et al., Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia, QJM, vol.97, issue.8, pp.499-506, 2004.
DOI : 10.1093/qjmed/hch088

URL : https://academic.oup.com/qjmed/article-pdf/97/8/499/4508204/hch088.pdf

A. Antonelli, S. M. Ferrari, A. Corrado, D. Domenica, A. Fallahi et al., Autoimmune thyroid disorders, Autoimmunity Reviews, vol.14, issue.2, pp.174-180, 2015.
DOI : 10.1016/j.autrev.2014.10.016

M. Armengol, M. Juan, A. Lucas-martín, M. Fernández-figuera, D. Jaraquemada et al., Thyroid Autoimmune Disease, The American Journal of Pathology, vol.159, issue.3, pp.861-73, 2001.
DOI : 10.1016/S0002-9440(10)61762-2

P. Attia, G. Q. Phan, M. A. , R. M. , Q. M. et al., Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti???Cytotoxic T-Lymphocyte Antigen-4, Journal of Clinical Oncology, vol.23, issue.25, pp.6043-53, 2005.
DOI : 10.1200/JCO.2005.06.205

D. L. Barber, W. E. Masopust, D. Zhu, B. , A. J. Sharpe et al., Restoring function in exhausted CD8 T cells during chronic viral infection, Nature, vol.111, issue.7077, pp.682-687, 2006.
DOI : 10.1016/S0092-8674(02)01139-X

G. M. Bartelds, W. G. Stapel, S. Aarden, L. , L. W. et al., High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment, Annals of the Rheumatic Diseases, vol.65, issue.9, pp.1249-1250, 2006.
DOI : 10.1136/ard.2005.049858

R. Belkhir, L. Bure, S. Dunogeant, L. Marabelle, A. Hollebecques et al., Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment, Annals of the Rheumatic Diseases, vol.76, issue.10, pp.1747-50, 2017.
DOI : 10.1136/annrheumdis-2017-211216

A. Bizhanova and P. Et-kopp, The Sodium-Iodide Symporter NIS and Pendrin in Iodide Homeostasis of the Thyroid, Endocrinology, vol.150, issue.3, pp.1084-90, 2009.
DOI : 10.1210/en.2008-1437

V. Boussiotis, Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway, New England Journal of Medicine, vol.375, issue.18, pp.1767-78, 2016.
DOI : 10.1056/NEJMra1514296

J. R. Brahmer, D. C. Wollner, I. , P. J. Picus, J. et al., Phase I Study of Single-Agent Anti???Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates, Journal of Clinical Oncology, vol.28, issue.19, pp.3167-75, 2010.
DOI : 10.1200/JCO.2009.26.7609

O. Brand, J. Barrett, M. Simmonds, P. Newby, C. Mccabe et al., Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease, Human Molecular Genetics, vol.18, issue.9, pp.1704-1717, 2009.
DOI : 10.1093/hmg/ddp087

L. E. Braverman and D. Cooper, Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text, 2012.

T. H. Brix and L. Hegedüs, Twin studies as a model for exploring the aetiology of autoimmune thyroid disease, Clinical Endocrinology, vol.18, issue.4, pp.457-464, 2012.
DOI : 10.1038/ejhg.2009.156

C. T. , R. A. Bedard, P. L. , S. L. Hansen, and A. R. , A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors, Annals of Oncology, vol.26, issue.9, pp.1824-1853, 2015.

N. H. Chiu and C. T. , Advances in immunoassay technology, 2012.
DOI : 10.5772/1967

C. Français and . Pathologistes, Polycopié d'enseignement d'Anatomie pathologique Disponible sur, 2011.

R. Costa, C. B. Agulnik, M. , R. A. Pai, S. G. Villaflor et al., Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials, Oncotarget, vol.8, issue.5, pp.8910-8930, 2017.
DOI : 10.18632/oncotarget.13315

M. Herbomez and J. Wémeau, Exploration de l'auto-immunité thyroïdienne : apport du laboratoire, Annales de Biologie Clinique, vol.59, issue.6, pp.717-723, 2001.

P. J. Davies, A. Shih, L. H. , M. L. , and D. F. , Thyroxine Promotes Association of Mitogen-activated Protein Kinase and Nuclear Thyroid Hormone Receptor (TR) and Causes Serine Phosphorylation of TR, Journal of Biological Chemistry, vol.273, issue.48, pp.38032-38071, 2000.
DOI : 10.1006/bbrc.1996.0777

D. Velasco, G. Je, Y. Bossé, D. , A. M. Ott et al., Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients, Cancer Immunology Research, vol.5, issue.4, pp.312-318, 2017.
DOI : 10.1158/2326-6066.CIR-16-0237

H. Dong, S. S. , S. D. Tamura, H. Hirano, F. et al., Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion, Nature Medicine, vol.49, issue.8, pp.793-800, 2002.
DOI : 10.1002/1531-8249(20010201)49:2<146::AID-ANA34>3.0.CO;2-E

M. S. Elston, S. Sehgal, D. Toit, S. Yarndley, T. et al., Factitious Graves' Disease Due to Biotin Immunoassay Interference???A Case and Review of the Literature, The Journal of Clinical Endocrinology & Metabolism, vol.101, issue.9, pp.3251-55, 2016.
DOI : 10.1210/jc.2016-1971

Y. Fujisawa, K. Yoshino, A. Otsuka, T. Funakoshi, T. Fujimura et al., Fluctuations in routine blood count might signal severe immunerelated adverse events in melanoma patients treated with nivolumab, Journal of Dermatological Science, 2017.

M. Gauci, P. Laly, T. Vidal-trecan, B. Baroudjian, J. Gottlieb et al., Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review. Cancer immunology, immunotherapy: CII, 2017.
DOI : 10.1007/s00262-017-2033-8

J. L. Gdwin, S. Jaggi, I. Sirisena, P. Sharda, R. A. Mehra et al., Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer, Journal for ImmunoTherapy of Cancer, vol.53, issue.2, p.40, 2017.
DOI : 10.2337/diabetes.53.2.384

S. Gough and M. Simmonds, The HLA region and autoimmune disease: associations and mechanisms of action, Curr Genomics, vol.8, pp.453-65, 2007.

T. Hara, S. Fu, and J. Hansen, Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen), Journal of Experimental Medicine, vol.161, issue.6, pp.1513-1524, 1985.
DOI : 10.1084/jem.161.6.1513

H. Hashimoto, Zur Kenntnis der Lymphomatösen Veränderung der Schilddrüse (Struma lymphomatosa) Archiv für Klinische Chirurgie, pp.219-248, 1912.

J. C. Hassel, L. Heinzerling, J. Aberle, O. Bohr, E. T. Grimm et al., Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions, Cancer Treatment Reviews, vol.57, pp.36-49, 2017.
DOI : 10.1016/j.ctrv.2017.05.003

Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo, Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death, The EMBO journal, vol.11, issue.11, pp.3887-95, 1992.

K. Ishikawa, T. Saito, T. Yamate, Y. Kai, T. Sakai et al., A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms, European journal of dermatology, vol.27, issue.2, pp.184-185, 2017.

. Anti-carcinoembryonic, Antigen Monoclonal Antibody in the Treatment of Patients with Metastatic Medullary Thyroid Carcinoma, Cancer, vol.85, pp.1828-1842, 1999.

Y. Kochi, R. Yamada, A. Suzuki, J. Harley, S. Shirasawa et al., A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities, Nature Genetics, vol.274, issue.Suppl 1, pp.478-85, 2005.
DOI : 10.1074/jbc.274.25.17837

K. Kitajima, K. Ashida, N. Wada, R. Suetsugu, Y. Takeichi et al., Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab, Japanese Journal of Clinical Oncology, vol.47, issue.5, pp.463-466, 2017.
DOI : 10.1093/jjco/hyx018

M. H. Kroll and E. R. , Interference with clinical laboratory analyses, Clinical Chemistry, vol.40, issue.11, pp.1996-2005, 1994.

A. Kroner, M. Mehling, B. Hemmer, P. Rieckmann, T. K. Mäurer et al., A PD-1 polymorphism is associated with disease progression in multiple sclerosis, Annals of Neurology, vol.25, issue.1, pp.50-57, 2005.
DOI : 10.4049/jimmunol.170.7.3637

M. F. Krummel and A. J. , CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells, Journal of Experimental Medicine, vol.183, issue.6, pp.2533-2573, 1996.
DOI : 10.1084/jem.183.6.2533

V. Kumar, N. Chaudhary, M. Garg, F. C. Soni, P. et al., Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy, Frontiers in Pharmacology, vol.8, 2017.

S. Lee, Y. Lee, D. Woo, R. Song, E. Park et al., Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population, 2006.

C. Lowe, J. Cooper, T. Brusko, N. Walker, D. Smyth et al., Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes, Nature Genetics, vol.1, issue.9, pp.1074-82, 2007.
DOI : 10.1086/338007

C. Magnan, Mode d'action des hormones thyroïdiennes. Les Récepteurs nucléaires, Disponible sur

M. Reck, D. Rodríguez-abreu, R. A. Hui, R. Cs?szi, T. Fülöp et al., Pembrolizumab versus Chemotherapy for PD-L1???Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.375, issue.19, pp.1823-1856, 2016.
DOI : 10.1056/NEJMoa1606774

K. Matsumura, K. Nagasawa, Y. Oshima, S. Kikuno, K. Hayashi et al., Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab, Journal of Diabetes Investigation, vol.2, 2017.
DOI : 10.1007/s12185-016-2101-4

D. S. Mcleod and C. D. , The incidence and prevalence of thyroid autoimmunity, Endocrine, vol.75, issue.3, pp.252-65, 2012.
DOI : 10.1001/jama.1978.03280350066018

S. M. Mclachlan and B. Rapoport, Thyroid Peroxidase as an Autoantigen, Thyroid, vol.17, issue.10, pp.939-948, 2007.
DOI : 10.1089/thy.2007.0169

S. Mongolu, A. A. Mozley, E. Nasruddin, and A. , Heterophilic antibody interference affecting multiple hormone assays: Is it due to rheumatoid factor?, Scandinavian Journal of Clinical and Laboratory Investigation, vol.48, issue.3, pp.76-240, 2016.
DOI : 10.1210/jc.2014-4023

D. L. Morganstein, Z. Lai, L. Spain, S. Diern, D. Levine et al., Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma, Clinical Endocrinology, vol.21, issue.4, pp.614-620, 2017.
DOI : 10.1158/1078-0432.CCR-14-2353

P. R. Newby, E. L. Roberts-davies, O. J. Brand, H. J. , F. J. Gough et al., Tag SNP screening of the PDCD1 gene for association with Graves? disease, Clinical Endocrinology, vol.13, issue.1, pp.125-128, 2007.
DOI : 10.1111/j.1365-2265.2006.02608.x

C. Nielsen, D. Hansen, S. Husby, J. B. Lillevang, and S. T. , Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes, Tissue Antigens, vol.167, issue.6, pp.492-497, 2003.
DOI : 10.1084/jem.192.7.1027

H. Nishimura, M. Nose, H. Hiai, N. Minato, and T. Honjo, Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor, Immunity, vol.11, issue.2, pp.141-151, 1999.
DOI : 10.1016/S1074-7613(00)80089-8

Y. Oppenheim, Y. Ban, and Y. Tomer, Interferon induced Autoimmune Thyroid Disease (AITD): a model for human autoimmunity, Autoimmunity Reviews, vol.3, issue.5, pp.388-393, 2004.
DOI : 10.1016/j.autrev.2004.03.003

D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, vol.12, issue.4, pp.252-264, 2012.
DOI : 10.1038/nrc3237

E. Pawlak-adamska, O. Nowak, L. Karabon, A. Pokryszko-dragan, A. Partyka et al., PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS, Journal of Neuroimmunology, vol.305, pp.115-127, 2017.
DOI : 10.1016/j.jneuroim.2017.02.006

D. I. Philips, O. C. Baird, J. Huckle, A. Rees-smith, and B. , Is Birthweight Associated with Thyroid Autoimmunity? A Study in Twins, Thyroid, vol.12, issue.5, pp.377-380, 2004.
DOI : 10.1089/105072502760043440

S. Piehl, H. C. Scanlan, T. S. , K. J. Thyronamines?past, and F. Present, Thyronamines???Past, Present, and Future, Endocrine Reviews, vol.32, issue.1, pp.64-80, 2011.
DOI : 10.1210/er.2009-0040

URL : https://academic.oup.com/edrv/article-pdf/32/1/64/10335167/edrv0064.pdf

D. Ricquier and . Bouillaud, Les prot??ines d??couplantes mitochondriales., m??decine/sciences, vol.14, issue.8-9, pp.889-97, 1998.
DOI : 10.4267/10608/1160

C. Robert, L. G. Brady, B. Dutriaux, C. Maio, M. Mortier et al., Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-330, 2015.
DOI : 10.1056/NEJMoa1412082

URL : https://hal.archives-ouvertes.fr/hal-00872683

B. Rousset, Le cheminement de l'iode dans la glande thyroïde, Annales d'Endocrinologie, vol.64, issue.1, pp.4-7, 2003.

H. Sakahara, R. J. , C. J. , L. M. , L. M. Larson et al., In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients, Journal of Nuclear Medicine, issue.8, pp.30-1311, 1989.

H. Sakai, G. Fukuda, N. Suzuki, C. Watanabe, and M. Odawara, Falsely Elevated Thyroid-Stimulating Hormone (TSH) Level Due to Macro-TSH, Endocrine Journal, vol.56, issue.3, pp.435-440, 2009.
DOI : 10.1507/endocrj.K08E-361

R. Sapin and J. Schlienger, Dosages de thyroxine (T4) et tri-iodothyronine (T3) : techniques et place dans le bilan thyroïdien fonctionnel, Annales Biologie Clinique, vol.61, pp.411-420, 2003.

R. Sapin, Interférences dans les immunodosages : mécanismes et conséquences en endocrinologie. Annales d'Endocrinologie, pp.415-425, 2008.
DOI : 10.1016/j.ando.2008.04.002

D. Smyth, J. Cooper, J. Collins, J. Heward, J. Franklyn et al., Replication of an Association Between the Lymphoid Tyrosine Phosphatase Locus (LYP/PTPN22) With Type 1 Diabetes, and Evidence for Its Role as a General Autoimmunity Locus, Diabetes, vol.53, issue.11, pp.3020-3023, 2004.
DOI : 10.2337/diabetes.53.11.3020

R. Thibaut, G. Vincke, E. Depiereux, and M. Raes, Vésicules thyroïdiennes. Atlas d'anatomie humaine et animale, Disponible sur

C. B. Thompson, T. Lindsten, J. A. Ledbetter, S. L. Kunkel, Y. H. et al., CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines., Proceedings of the National Academy of Sciences, vol.86, issue.4, pp.1333-1370, 1989.
DOI : 10.1073/pnas.86.4.1333

R. H. Thompson, G. M. , C. J. , L. C. Dong, H. et al., Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target, Proceedings of the National Academy of Sciences, vol.86, issue.19, pp.17174-79, 2004.
DOI : 10.1093/jnci/86.19.1470

Y. Tomer and T. Davies, Searching for the Autoimmune Thyroid Disease Susceptibility Genes: From Gene Mapping to Gene Function, Endocrine Reviews, vol.24, issue.5, pp.694-717, 2003.
DOI : 10.1210/er.2002-0030

H. Trainer, P. Hulse, C. E. Higham, P. Trainer, and P. Lorigan, Hyponatraemia secondary to nivolumabinduced primary adrenal failure. Endocrinology, Diabetes & Metabolism Case Reports, 2016.
DOI : 10.1530/edm-16-0108

URL : http://doi.org/10.1530/edm-16-0108

H. Ueda, J. Howson, L. Esposito, J. Heward, H. Snook et al., Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease, Nature, vol.52, issue.6939, pp.506-517, 2003.
DOI : 10.1093/nar/gnf052

Y. Usui, H. Udagawa, S. Mastsumoto, K. Imai, K. Ohashi et al., Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by??Nivolumab in Patients with Non???Small Cell Lung??Cancer, Journal of Thoracic Oncology, vol.12, issue.5, pp.41-43, 2017.
DOI : 10.1016/j.jtho.2016.12.015

K. A. Von-basedow, Exophthalmus durch Hypertrophie des Zellgewebes in der Augenhöhle. Wochenschrift für die gesammte Heilkunde, pp.197-204228, 1840.

W. J. , D. Angelo, S. P. Minor, D. , H. F. Gutzmer et al., Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. The Lancet, Oncology, vol.16, issue.4, pp.375-384, 2015.

J. Wemeau, Les maladies de la thyroïde, 2010.

W. M. , T. K. Yeung, and S. J. , Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism, The American Journal of Emergency Medicine, vol.35, issue.7, p.1039, 2017.

J. Wolchok, J. Weber, O. Hamid, C. Lebbé, M. Maio et al., Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials, Cancer Immun J Acad Cancer Immunol, vol.10, 2010.

R. S. Yalow and S. A. Berson, Assay of Plasma Insulin in Human Subjects by Immunological Methods, Nature, vol.18, issue.4699, pp.1648-1697, 1959.
DOI : 10.1038/1841648b0

S. A. Zouwail, O. Toole, A. M. , C. P. Begley, and J. P. , Influence of Thyroid Hormone Autoantibodies on 7 Thyroid Hormone Assays, Clinical Chemistry, vol.54, issue.5, pp.927-928, 2008.
DOI : 10.1373/clinchem.2007.099770